

1 **Patients at risk of pulmonary fibrosis Post Covid-19:**

2 **Epidemiology, pulmonary sequelaes and humoral response**

3
4
5 Miriam Hernández Porto^{1,2¶*}, Teresa Delgado^{1¶}, Armando Aguirre-Jaime^{3&}, María Jose Ramos^{1&},
6 Silvia Campos^{1&}, Orlando Acosta⁴, Ana Belén Llanos⁴, María Lecuona^{1&}.

7
8
9
10 ¹ Microbiology Service. University Hospital of the Canary Islands, La Laguna, Tenerife, Spain.

11 ² Faculty of Medicine. University of La Laguna. La Laguna, Tenerife, Spain.

12 ³Statistics department. Institute for Healthcare Research of the Nursing School of Santa Cruz de
13 Tenerife, Tenerife, Spain.

14 ⁴Pneumology Department. University Hospital of the Canary Islands. La Laguna, Tenerife, Spain.

15
16
17
18 *Corresponding author

19 E-mail: portomiri@hotmail.com (MHP)

20

21 ¶ These authors contributed equally to this work.

22 & These authors also contributed equally to this work.

23

24

25

26

27

28

29 **Abstract**

30 **Background**

31 The COVID-19 pandemic is one of the greatest public health problems. Our aims were to describe
32 epidemiological characteristics, know the amount of protective antibodies and their permanence
33 after a COVID-19 primary infection in patients with risk of pulmonary fibrosis.

34 **Methods**

35 Descriptive epidemiological and follow-up study of the humoral response in patients at risk of
36 pulmonary fibrosis Post-Covid-19 hospitalized, between March and October 2020, and who were
37 followed up for a one year after hospital discharge.

38 **Results**

39 72 patients participated in the study, 52 showed pre-existing chronic comorbidities. COVID-19
40 clinical severity was rated in 6% mild, 58% as moderate and 36% as severe. After a year of follow-
41 up, the forty percent had pulmonary sequelae, the most frequent (20%) was mild pulmonary
42 fibrosis. Any case of reinfection was detected. All patients presented RBD IgG antibodies and 88%
43 presented IgA antibodies after 8-9 months. The amount of RBD IgG was similar at 4-5 and 8-9
44 months post-Covid. There was no difference when level of RBD IgG according to the severity of
45 the COVID-19 ($p=0.441$, $p=0.594$).

46 **Conclusions**

47 Mild pulmonary fibrosis sequelae is exceptional but was detected in a high percentage. The amount
48 of RBD IgG is maintained throughout the convalescent phase and seems to protect against new
49 reinfections despite of emerging viral variants. However, seems not predict the developed or not of
50 pulmonary fibrosis.

51

52

53 **Introduction**

54 The COVID-19 pandemic continues to spread worldwide and is one of the greatest public health
55 problems in the world. The severity of the COVID-19 picture is probably due to a previous
56 deterioration of the immune system [1] due to the comorbidities, such as those reported Williamson
57 et al., [2]: cardiovascular disease, diabetes, respiratory disease including severe asthma, obesity,
58 history of hematological malignancy, cancer, kidney, liver, neurological and autoimmune
59 conditions. Many patients are symptomatic to some degree after COVID-19 Infection but
60 Pulmonary fibrosis is exceptional [3].

61 Animal models have demonstrated how SARS CoV-2 infection in macaques [4] provides effective
62 protection against reinfection by this virus, probably due to the rapid immune control that occurs
63 thanks to the neutralizing action of the antibodies. This action is centered on its ability to neutralize
64 the receptor-binding domain (RBD) of the virus in the S1 subunit, thus preventing its binding to the
65 cellular receptor angiotensin-converting enzyme 2 (ACE2) and therefore avoiding the entry of the
66 virus into the cell. In addition, several studies have been carried out on the early use of plasma from
67 convalescent patients with high titers of neutralizing antibodies as a therapeutic option in patients
68 with COVID-19 [5,6].

69 Finally, the risk of reinfection is considerable, due to several reasons: the absence of a threshold of
70 antibodies that predict protection, the permanence of these antibodies in the organism after a
71 primary infection and the emerging viral variants.

72 Our aims were to describe epidemiological characteristics, know the amount of protective
73 antibodies and their permanence after COVID-19 primary infection in patients with risk of
74 pulmonary fibrosis.

75

76 **Materials and Methods**

77 Descriptive characteristics and follow-up results of the humoral response in patients with a
78 diagnosis of SARS-CoV-2 confirmed by RT-PCR and hospitalized at the Hospital Universitario de
79 Canarias (Spain), between March and October 2020, and who were followed up after hospital
80 discharge at the Multidisciplinary Interstitial Lung Disease Unit of this Hospital. These patients had
81 to present at least one of the following conditions to be referred to such consultation: persistence of
82 pathological alterations in the chest X-ray and/or having required special ventilatory support
83 devices during their admission (high-flow nasal spectacles, noninvasive ventilation or intubation
84 and mechanical ventilation). This follow-up ended when respiratory clinical normalization was
85 observed and complete or almost complete involution of the radiological alterations initially
86 visualized was confirmed. During follow-up and for the evaluation of possible post COVID-19
87 pulmonary sequelae pulmonary function tests and imaging tests (pulmonary ultrasound and high
88 resolution computed axial tomography) were performed at 6 weeks (in all cases) and at 3-6 months
89 and one year (those who had to be followed up due to incomplete recovery in the initial and
90 successive visits).

91 Patient volunteers signed their informed consent and were subsequently scheduled for serum
92 sampling at 4-5 months and 8-9 months after COVID-19 infection.

93 We analyzed different antibodies; RBD-specific IgG, Nucleocapsid IgG, and Spike 1-RBD IgM
94 antibodies determined by Abbott chemiluminescent microparticle assays (CMIA): SARS-CoV-2
95 IgG II Quant, SARS-CoV-2 IgG and SARS-CoV-2 IgM using the ARCHITECT i 2000 SR system,
96 following the manufacturer's instructions.

97 IgG RBD measurements were transformed to the WHO [7] international standard BAU/mL in order

98

99 to obtain comparable of antiSARS-CoV-2 antibody quantification at the international level.

100 IgA Spike and IgM Nucleocapsid antibodies were determined using EUROIMMUN enzyme-linked
101 immunosorbent assay (ELISA); Anti-SARS-CoV-2 ELISA IgA and Anti-SARS-CoV-2 NCP
102 ELISA IgM (Euroimmun, Lübeck, Germany) according to the manufacturer's instructions on the
103 Dynex DS2 ELISA System platform.

104 Clinical variables of the patients were also collected by reviewing the medical history such as: sex
105 and age, comorbidities considered as risk factors for worse prognosis [2], being a smoker or former
106 smoker, degree of severity of COVID-19 disease according to the WHO guidelines (Clinical
107 Management of COVID-19 Patients-Interim Guidance)[8], hospital admission service, hospital stay,
108 duration of the acute phase of the disease, development of pneumonia, measurement of oxygen
109 saturation and type of ventilatory support required during admission, months of post-discharge
110 follow-up, clinical resolution after one year of follow-up, reinfection with SARS-CoV-2.

111 The characteristics of the sample are presented by summarizing the nominal variables with the
112 absolute and relative frequency of their component categories and the numerical scale variables
113 with mean(SD) or median(minimum-maximum) according to their normal or non-normal
114 distribution confirmed with the Kolmogorov-Smirnov test. Comparisons of the changes in the
115 frequencies of the ranges of antibody determinations according to each specific cut-off point from
116 4-5 to 8-9 months were performed with the Pearson's chi-squared test or Fisher's exact test.
117 Comparisons of changes in IgG measured in BAU/ml compared to RBD from 4-5 to 8-9 months, in
118 general, and stratified by COVID-19 severity were performed with the Wilcoxon test for paired
119 samples. Comparison of these same determinations for the same period according to COVID-19
120 severity was performed with the U Mann-Whitney test.

121

122 All hypothesis contrast tests were bilateral at a significance level $p \leq 0.05$ and the calculations
123 involved were performed with the support of the SPSS 25.0™ statistical data processing package
124 from IBM Co®.

125 **Ethical Approval statement**

126 The study was approved by Ethical Committee with the code CHUC_2020_68.

127 **Results**

128 A total of 72 patients who met the inclusion criteria and gave their consent participated in the study.
129 The total sample of participants had an age of 60(30) years in a range of 32-89 years, 53% were
130 women. Seventy nine percent of the patients showed pre-existing chronic comorbidities. The
131 distribution of comorbidities was as follows: 58% hypertension, 39% type 2 diabetes, 19% chronic
132 pulmonary disease, 15% heart disease, 10% chronic kidney disease, 7% oncologic disease and 1%
133 cerebrovascular disease. A total of 75% had 2 or more comorbidities. Some 36% were smokers or
134 former smokers. The degree of clinical severity of COVID-19 was rated as mild in 6% mild,
135 moderate in 58% and severe in 36%. Ninety four percent of the patients with pre-existing chronic
136 comorbidities, showed moderate and severe COVID-19.

137 Patients were hospitalized in different departments: 54% in Internal Medicine-Infectious Diseases,
138 25% in Pneumology, 18% in Intensive Care Units and 3% in Home Hospitalization Unit. Hospital
139 stay was 22 (1-41) days. The duration of the acute phase was 25(8-62) days. During the acute phase
140 of the disease, 94% developed pneumonia. Forty-nine percent required no ventilatory support, while
141 25% required high-flow nasal spectacles, 13% noninvasive mechanical ventilation and 13%
142 invasive according to the severity of the process. In cases with moderate and severe COVID the
143 oxygen saturation during admission was 88(0,7) % in a range of 70-98%. 13 % of patients are still

144

145 under clinical follow-up due to post COVID-19 pulmonary sequelae after one year and in the rest of
 146 patients the post-discharge clinical follow-up time by the Multidisciplinary Unit of Interstitial Lung
 147 Diseases of the Hospital was 9(1-12) months.

148 Of total patients, forty percent had pulmonary sequelae, including seventeen percent with minimal
 149 parenchymal alterations with no clinical or functional repercussions, three percent with had ground-
 150 glass infiltrates and twenty percent mild with pulmonary fibrosis.

151 40 out of 72 patients participated in the antibody analysis; 20 attended the sample collection for
 152 antibody determination at 4-5 months and at 8-9 months post COVID-19 and other 20 at 8-9
 153 months post COVID-19. All of them had moderate or severe of COVID, and thirty six percent had
 154 minimal parenchymal sequelae with no clinical or functional repercussions, and no one developed
 155 pulmonary fibrosis.

156 The results of the humoral response to SARS-CoV-2 at 4-5 months and 8-9 months post Covid-19
 157 infection are shown in Table 1.

158 **Table 1.** Humoral response to SARS-CoV-2 at 4-5 months and 8-9 months after Covid-19
 159 infection.

DETERMINATION n(%)	At 4-5 months post infection				At 8-9 months post infection			
	POSITIVE	NEGATIVE	UNDET.	INDEX median (min-max)	POSITIVE	NEGATIVE	UNDET.	INDEX median (min-max)
IgG RBD	20 (100)	0 (0)	---	---	40 (100)	0 (0)	---	---
IgG nucleocapsid	16 (80)	1 (5)	3 (15)	3.8 (0.6-8.6)	19 (47.5)	16 (40)	5 (12.5)	1.2 (0.1-6.6)
IgM Spike1	5 (25)	15 (75)	---	0.2 (0.0-4.7)	9 (22.5)	31 (77.5)	---	0.2 (0.0-4.2)
IgA Spike1	18 (90)	0 (0)	2 (10)	3.2 (0.8-5.5)	35 (87.5)	0 (0)	5 (12.5)	3.7 (0.8-10)
IgM nucleocapsid	1 (5)	1 (5)	18 (90)	0.3 (0.0-1.8)	1 (2.5)	36 (90)	3 (7.5)	0.2 (0.0-2.8)

160

161 Positivity to the combination of IgG RBD, IgA Spike and IgM Spike was 25% at 4-9 months and
 162 23% at 8-9 months.

163 The difference in IgM Spike 1 from 4-5 months to 8-9 months reached significance ($p=0.009$),
 164 while the difference in IgA Spike 1 between the two periods reached marginal significance
 165 ($p=0.053$). The differences of IgG Nucleocapsid and IgM Nucleocapsid did not reach statistical
 166 significance. The amount of IgG RBD antibody was 111.9(11.3-642.7) BAU/ml in the period 4-5
 167 months post COVID-19 and 111.8(21.2-1820) BAU/ml in the period 8-9 months post COVID-19
 168 ($p=0.391$).

169 The amount of RBD IgG antibodies produced at 4-5 and 8-9 months post-infection according to the
 170 degree of severity of the COVID-19 disease suffered are shown in Table 2. No statistical
 171 significance of their differences was found either within or between periods.

172 **Table 2.** Amount of RBD IgG Ab measured in BAU/ml as a function of disease severity, at 4-5
 173 months and at 8-9 months post Covid-19 infection.

174

COVID SEVERITY	IgG RBD positive		IgG (BAU/ml) median (min-máx)		p-Value
	at 4-5 months	at 8-9 months	at 4-5 months	at 8-9 months	
MODERATE n (%)	9 (45)	22 (55)	91.3 (43.9-577.9)	130.9 (24.7-1,820)	0.441
SEVERE n (%)	11 (55)	18 (45)	148.4 (11.3-642.7)	94.6 (21.2-1,123.4)	0.594
p-Value	---	---	0.503	0.251	---

175

176 To date (February 2022) we have not detected any case of re-infection requiring a microbiological
 177 diagnosis in our study.

178 **Discussion**

179 This paper presents a study of patients with a microbiological diagnosis of SARS-CoV-2 infection,
180 who required hospital admission. A high percentage of patients had pre-existing chronic
181 comorbidities and all of them suffered a moderate or severe course of the disease. Different studies
182 have related the severity of the COVID-19 infection with previous the comorbidities presented. We
183 found that hypertension and type 2 diabetes were the main diseases, coinciding with other authors
184 such as Huang et al [8].

185 Half of the patients required respiratory support measures: 25% with high-flow nasal spectacles,
186 13% noninvasive ventilation and 13% of patients required IMV, a percentage higher than in other
187 series [9].

188 After a year of follow-up, forty percent of the patients had pulmonary sequelae, Huang C et al.,[10]
189 described that most patients (76%) are symptomatic to some degree after six months of COVID-19
190 infection, the most common symptomatology being fatigue and muscle weakness in 63%, insomnia
191 in 26% and anxiety in 23%. Also, the alteration of pulmonary function presented a percentage of
192 22-56% of cases, being higher in those cases that had more severe cases of COVID-19 disease
193 during the acute phase [10]. Similar results were obtained by Lombardo et al. one year after SARS-
194 COV-2 infection in hospitalized patients, reaching a pulmonary involvement of 37% [11]. Within
195 the pulmonary sequelae, the most frequent are interstitial thickening, ground-glass infiltrates [11] in
196 our study we found that most frequent was mild pulmonary fibrosis.

197 Pulmonary fibrosis is exceptional and risk factors for its development are considered to be age,
198 severity of COVID-19 disease, prolonged stay in ICU, need for mechanical ventilation, smoking
199 and alcoholism [3]. In our study twenty percent of patients had mild pulmonary fibrosis and most

200

201 patients suffered severe COVID-19 during the acute phase.

202 We have not detected any case of reinfection that required a microbiological diagnosis;
203 nevertheless, we are aware that mild or asymptomatic self-limited cases could go unnoticed. On the
204 other hand, authors such as Havervall et al.,[12] conclude that the vast majority of patients who
205 present a positive Spike IgG result 8 months after COVID-19 infection have a reduced risk of both
206 asymptomatic and mild reinfection, regardless of the severity of the initial COVID-19 infection.

207 Of the 40 patients who participated in the antibody analysis all presented RBD IgG after 8-9 months
208 post COVID-19 infection, which is in line with previously published studies [13]; however, to our
209 knowledge we are the first to quantify these antibodies in International Units (BAU/ml).

210 In addition, 47% of patients were positive for IgG Nucleocapsid and 2.5% for IgM Nucleocapsid,
211 coinciding with other studies such as Ripperger et al., [14] where they report that the antibodies
212 compared to Nucleocapsid decrease more rapidly than Ab compared to RBD. Likewise, 88%
213 presented positivity to IgA Spike in line with other studies such as that of Dan et al., [15] which
214 also detects it in serum in the majority of subjects 6-8 months after infection. Twenty-three percent
215 of patients were positive for RBD IgG, Spike IgA Spike and Spike 1-RBD IgM, which could
216 contribute to a greater capacity to neutralize the virus in these patients [16].

217 In the analysis of the evolution of antibodies from 4-5 months to 8-9 months we found no difference
218 in the amount of RBD IgG detected, so that similar levels of Spike IgG A were maintained in both
219 periods of convalescence analyzed, something already observed in other studies [15,17]. However,
220 we did find a significant decrease in Spike 1-RBD IgM, coinciding with other authors such as

221 Gaebler et al [18]. It has been described in the literature that during the acute phase of the disease
222 there are higher levels of IgG to S1 and Nucleocapsid in patients with severe COVID-19 than in

223

224 those with milder disease [18, 19]. However, in our study we did not find difference when the level
225 of RBD IgG according to the severity of the COVID-19 disease suffered was compared, coinciding
226 with other authors such as Sandberg et al.,[17] probably because all our population had a diagnosis
227 of pneumonia and were stratified as severe or moderate COVID-19, without having patients with
228 mild or asymptomatic disease, as well as the period after the COVID-19 infection analyzed. On
229 the other hand we observed that the amount of RBD IgG antibodies is maintained throughout the
230 convalescent COVID-19 phase and that the amount that remains in the medium term seems to
231 protect against new reinfections despite of emerging viral variants.

232 Finally, we believe that the development or not of pulmonary fibrosis is probably independent of
233 the amount of RBD IgG generated, since we observed that regardless of the level of antibodies
234 maintained, a considerable proportion of COVID-19 patients developed discrete interstitial
235 parenchymal alterations.

236 There are some limitations to this study. The first one is that the sample size is small, which
237 undermines the power of the study. On the other hand, in our study the majority of patients suffered
238 a moderate-severe degree of severity of the disease, who were those who required follow-up by the
239 multidisciplinary consultation, so that the humoral immune response profile cannot be applied to
240 patients with a mild degree of severity or to asymptomatic patients. Another limitation is that even
241 if no new reinfections were detected, these may have been asymptomatic, however, these patients
242 have a greater neutralizing capacity thanks to the positivity of IgG and IgA.

243 Taking these limitations into consideration, our study describes a high percentage of mild
244 pulmonary fibrosis development in patients who presented at least one of the following conditions:

245 persistence of pathological alterations in the chest X-ray and/or having required special ventilatory
246 support devices during their admission.

247

248 Acknowledgments

249 The authors would like to thank the Microbiology Laboratory Technicians (Maria Desiree Ruiz and
250 Carmen Lorenzo), and the Infection Control nurses for their help with the procedures.

251 References

252 1. Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus
253 disease 2019 (Covid-19). *Diabetes Metab Res Rev*. 2021 Feb;37(2):e3377. doi: 10.1002/dmrr.3377.
254 Epub 2020 Jul 20. PMID: 32588943; PMCID: PMC7361201.

255
256 2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al., Factors
257 associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020 Aug;584(7821):430-
258 436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8. PMID: 32640463; PMCID: PMC7611074.

259
260 3. Chérrez-Ojeda I, Gochicoa-Rangel L, Salles-Rojas A, Mautong H. Seguimiento de los pacientes
261 después de neumonía por COVID-19. *Secuelas pulmonares [Follow-up of patients after COVID-19
262 pneumonia. Pulmonary sequelae]*. *Rev Alerg Mex*. 2020 Oct-Dec;67(4):350-369. Spanish. doi:
263 10.29262/ram.v67i4.847. PMID: 33631903.

264
265 4. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al., SARS-CoV-2
266 infection protects against rechallenge in rhesus macaques. *Science*. 2020 Aug 14;369(6505):812-
267 817. doi: 10.1126/science.abc4776. Epub 2020 May 20. PMID: 32434946; PMCID: PMC7243369.

268
269 5. Maor Y, Cohen D, Paran N, Israely T, Ezra V, Axelrod O, et al., Compassionate use of
270 convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and
271 association with IgG antibody levels in donated plasma. *EClinicalMedicine*. 2020 Sep;26:100525.
272 doi: 10.1016/j.eclinm.2020.100525. Epub 2020 Sep 9. PMID: 32923991; PMCID: PMC7480446.

273
274 6. Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Almusawi YA, et al., The
275 therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients
276 residing in respiratory care units in hospitals in Baghdad, Iraq. *Infez Med*. 2020 Sep 1;28(3):357-
277 366. PMID: 32920571.

278
279 7. WHO/BS.2020.2403 Establishment of the WHO International Standard and Reference Panel for anti-
280 SARS-CoV-2 antibody. Available from: [https://www.who.int/publications/m/item/WHO-BS-
281 2020.2403](https://www.who.int/publications/m/item/WHO-BS-2020.2403).

282
283 8. World Health Organization. 2020. Clinical Management of COVID-19 Patients- Interim
284 Guidance. World Health Organization, Geneva, Switzerland.

285
286 9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, et al., Clinical features of patients
287 infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020 Feb 15;395(10223):497-506.
288 doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: *Lancet*. 2020 Jan 30;: PMID:
289 31986264; PMCID: PMC7159299.

290

- 291 10. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al., 6-month consequences of COVID-19 in
292 patients discharged from hospital: a cohort study. *Lancet*. 2021 Jan 16;397(10270):220-232. doi:
293 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8. PMID: 33428867; PMCID: PMC7833295.
294
- 295 11. Lombardo MDM, Foppiani A, Peretti GM, Mangiavini L, Battezzati A, Bertoli S, et al., Long-
296 Term Coronavirus Disease 2019 Complications in Inpatients and Outpatients: A One-Year Follow-
297 up Cohort Study. *Open Forum Infect Dis*. 2021 Jul 16;8(8):ofab384. doi: 10.1093/ofid/ofab384.
298 PMID: 34386546; PMCID: PMC8344801.
299
- 300
- 301 12. Havervall S, Ng H, Jernbom Falk A, Greilert-Norin N, Månberg A, Marking U, Laurén I, et al.,
302 Robust humoral and cellular immune responses and low risk for reinfection at least 8 months
303 following asymptomatic to mild COVID-19. *J Intern Med*. 2022 Jan;291(1):72-80. doi:
304 10.1111/joim.13387. Epub 2021 Sep 27. PMID: 34459525; PMCID: PMC8661920.
305
- 306 13. Masiá M, Fernández-González M, Telenti G, Agulló V, García JA, Padilla S, et al., Durable
307 antibody response one year after hospitalization for COVID-19: A longitudinal cohort study. *J*
308 *Autoimmun*. 2021 Sep;123:102703. doi: 10.1016/j.jaut.2021.102703. Epub 2021 Jul 20. PMID:
309 34303083; PMCID: PMC8289631.
310
- 311 14. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al., Orthogonal
312 SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal
313 Durable Humoral Immunity. *Immunity*. 2020 Nov 17;53(5):925-933.e4. doi:
314 10.1016/j.immuni.2020.10.004. Epub 2020 Oct 14. PMID: 33129373; PMCID: PMC7554472.
315
- 316 15. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al., Immunological memory to
317 SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021 Feb 5;371(6529):eabf4063.
318 doi: 10.1126/science.abf4063. Epub 2021 Jan 6. PMID: 33408181; PMCID: PMC7919858.
319
- 320 16. Noval MG, Kaczmarek ME, Koide A, Rodriguez-Rodriguez BA, Louie P, Tada T, et al.,
321 Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization
322 capacities. *Sci Rep*. 2021 Mar 10;11(1):5538. doi: 10.1038/s41598-021-84913-3. PMID: 33692390;
323 PMCID: PMC7946906.
324
- 325 17. Sandberg JT, Varnaitè R, Christ W, Chen P, Muvva JR, Maleki KT, et al., SARS-CoV-2-
326 specific humoral and cellular immunity persists through 9 months irrespective of COVID-19
327 severity at hospitalisation. *Clin Transl Immunology*. 2021 Jul 5;10(7):e1306. doi:
328 10.1002/cti2.1306. PMID: 34257967; PMCID: PMC8256672.
329
- 330 18. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al., Evolution of
331 antibody immunity to SARS-CoV-2. *Nature*. 2021 Mar;591(7851):639-644. doi: 10.1038/s41586-
332 021-03207-w. Epub 2021 Jan 18. PMID: 33461210; PMCID: PMC8221082.
333
- 334 19. Horton DB, Barrett ES, Roy J, Gennaro ML, Andrews T, Greenberg P, et al., Determinants and
335 Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective
336 Cohort Study. *J Infect Dis*. 2021 Oct 28;224(8):1345-1356. doi: 10.1093/infdis/jiab411. PMID:
337 34387310; PMCID: PMC8436370.
338
- 339